Eli Gabayan

460 total citations
6 papers, 343 citations indexed

About

Eli Gabayan is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Eli Gabayan has authored 6 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Hematology and 2 papers in Genetics. Recurrent topics in Eli Gabayan's work include Protein Degradation and Inhibitors (6 papers), Multiple Myeloma Research and Treatments (6 papers) and Ubiquitin and proteasome pathways (2 papers). Eli Gabayan is often cited by papers focused on Protein Degradation and Inhibitors (6 papers), Multiple Myeloma Research and Treatments (6 papers) and Ubiquitin and proteasome pathways (2 papers). Eli Gabayan collaborates with scholars based in United States and Sweden. Eli Gabayan's co-authors include Marti McKinley, Sundar Jagannath, Elber S. Camacho, Jose Lutzky, Jeffrey L. Wolf, David P. Schenkein, David Irwin, John Crowley, Amitabha Mazumder and Brian G.M. Durie and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Eli Gabayan

6 papers receiving 332 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eli Gabayan United States	4	295	269	188	21	8	6	343
Cecilia Rus Italy	5	361 1.2×	248 0.9×	203 1.1×	34 1.6×	13 1.6×	12	378
Dixil Francis United States	4	231 0.8×	197 0.7×	100 0.5×	32 1.5×	18 2.3×	5	279
Clotilde Cangialosi Italy	8	433 1.5×	365 1.4×	259 1.4×	30 1.4×	17 2.1×	16	460
Marti McKinley United States	9	427 1.4×	395 1.5×	283 1.5×	35 1.7×	14 1.8×	17	507
Chiara Nicci Italy	4	403 1.4×	316 1.2×	188 1.0×	73 3.5×	9 1.1×	4	468
Agne Paner United States	9	160 0.5×	217 0.8×	114 0.6×	31 1.5×	18 2.3×	33	282
Adrienne Briggs United States	5	191 0.6×	142 0.5×	118 0.6×	21 1.0×	14 1.8×	8	214
Bart Barlogie United States	5	192 0.7×	215 0.8×	107 0.6×	63 3.0×	7 0.9×	9	290
S Triolo Italy	7	347 1.2×	223 0.8×	198 1.1×	36 1.7×	14 1.8×	13	367
Sandra Wear United States	7	236 0.8×	245 0.9×	107 0.6×	20 1.0×	8 1.0×	7	276

Countries citing papers authored by Eli Gabayan

Since Specialization

Citations

This map shows the geographic impact of Eli Gabayan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eli Gabayan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eli Gabayan more than expected).

Fields of papers citing papers by Eli Gabayan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eli Gabayan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eli Gabayan. The network helps show where Eli Gabayan may publish in the future.

Co-authorship network of co-authors of Eli Gabayan

This figure shows the co-authorship network connecting the top 25 collaborators of Eli Gabayan. A scholar is included among the top collaborators of Eli Gabayan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eli Gabayan. Eli Gabayan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Tomasson, Michael H., et al.. (2024). Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 144(Supplement 1). 1024–1024. 3 indexed citations

2.

Jagannath, Sundar, Brian G.M. Durie, Jeffrey L. Wolf, et al.. (2005). Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology. 129(6). 776–783. 299 indexed citations

3.

Jagannath, Sundar, Jeffrey L. Wolf, Elber S. Camacho, et al.. (2005). Bortezomib Therapy Alone and in Combination with Dexamethasone for Patients with Previously Untreated Multiple Myeloma.. Blood. 106(11). 783–783. 14 indexed citations

4.

Jagannath, Sundar, Jeffrey L. Wolf, Elber S. Camacho, et al.. (2004). First-line therapy with bortezomib (formerly PS-341) in patients with multiple myeloma (MM). Journal of Clinical Oncology. 22(14_suppl). 6551–6551. 3 indexed citations

5.

Jagannath, Sundar, Jeffrey L. Wolf, Elber S. Camacho, et al.. (2004). A Phase 2 Study of Bortezomib as First-Line Therapy in Patients with Multiple Myeloma.. Blood. 104(11). 333–333. 19 indexed citations

6.

Jagannath, Sundar, Jeffrey L. Wolf, Elber S. Camacho, et al.. (2004). First-line therapy with bortezomib (formerly PS-341) in patients with multiple myeloma (MM). Journal of Clinical Oncology. 22(14_suppl). 6551–6551. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact